Evidence map›Paper›PMID 40181993›Full record

ArticleFrontiers in immunology2025

Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients.

Allan Feng, Michael V Gonzalez, Muge Kalaycioglu, Xihui Yin, Melanie Mumau, Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Sarah E Chang, Shaurya Dhingra, Tea Dodig-Crnkovic and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Snapshot Look at Castleman Disease.Journal of cellular and molecular medicine · 2026
    Review
  2. Review
  3. Article
  4. Expert Perspective: Diagnosis and Treatment of Castleman Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Allan FengDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, United States.
Michael V GonzalezCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, PA, United States.
Muge KalayciogluDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, United States.
Xihui YinDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, United States.
Melanie MumauCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, PA, United States.
Saishravan ShyamsundarCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, PA, United States.
Mateo Sarmiento BustamanteCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, PA, United States.
Sarah E ChangDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, United States.
Shaurya DhingraDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, United States.
Tea Dodig-CrnkovicScience for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Jochen M SchwenkScience for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Tarun GargMyeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Kazuyuki YoshizakiDepartment of Biomolecular Science and Regulation, The Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan.
Frits van RheeMyeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
David C FajgenbaumCenter for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, PA, United States.
Paul J UtzDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, United States.

Funding

Computational models of naturally acquired immunity to falciparum malariaU01AI150741 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BUTTE, ATUL J, GREENHOUSE, BRYAN R · 2020 to 2024
$7.4M
mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026
$6.1M
Giant MagnetoResistive (GMR) Sensors for Measuring Influenza VaccineR01AI125197 · NIAID · STANFORD UNIVERSITY · PI UTZ, PAUL JOSEPH, WANG, SHAN X. · 2016 to 2021
$5.0M
FDA HHS R01 FD007632NHLBI NIH HHS R01 HL141408NIAID NIH HHS R01 AI125197NIAID NIH HHS U01 AI150741
6 · The paper itself

Abstract

Introduction: Idiopathic Multicentric Castleman Disease (iMCD) is a polyclonal lymphoproliferative disorder involving cytokine storms that can lead to organ failure and death. The cause of iMCD is unknown, but some clinical evidence suggests an autoimmune etiology. For example, connective tissue disorders (CTDs) and iMCD share many clinical features, and autoantibodies have been anecdotally reported in individual iMCD patients. This study investigates whether common autoantibodies are shared across iMCD patients. Methods: We assembled custom bead-based protein arrays consisting of 52 autoantigens traditionally associated with CTDs and 38 full-length cytokines and screened serum samples from 101 iMCD patients for IgG autoantibodies. We also screened samples with a 1,103-plex array of recombinant human protein fragments to identify additional autoantibody targets. Finally, we performed receptor blocking assays on select samples with anti-cytokine autoantibodies (ACAs) identified by array. Results: We found that an increased proportion of iMCD patients (47%) tested positive for at least one CTD-associated autoantibody compared to healthy controls (HC) (17%). Commonly detected CTD-associated autoantibodies were associated with myositis and overlap syndromes as well as systemic lupus erythematosus (SLE) and Sjögren's Syndrome (SS). ACAs were also detected in a greater proportion of iMCD patients (38%) compared to HC (10%), while the protein fragment array identified a variety of other autoantibody targets. One iMCD sample tested positive for receptor blocking against interferon-ω (IFNω). Discussion: IgG autoantibodies binding autoantigens associated with common CTDs and cytokines are elevated in iMCD patients compared to HC, suggesting that autoimmunity may be involved in iMCD pathogenesis.

Indexed as

AutoantibodiesCastleman DiseaseConnective Tissue DiseasesCytokinesAdultAgedAutoantigensFemaleHumansImmunoglobulin GMaleMiddle AgedYoung AdultAutoantibodiesAutoantigensCytokinesImmunoglobulin Gautoantibodyautoimmunityconnective tissue disordersiMCDluminexprotein arrayTAFRO

Identifiers

PMID40181993
PMCPMC11966032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.